{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:35Z","timestamp":1792113215352,"version":"4.4.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jid.2020.07.026","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T09:49:56Z","timestamp":1604569796000},"page":"484-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and\/or S\u00e9zary Syndrome"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"Pietro","family":"Quaglino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7458","authenticated-orcid":false,"given":"Paolo","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-7171","authenticated-orcid":false,"given":"Alessandro","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8201-346X","authenticated-orcid":false,"given":"Vieri","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-9034","authenticated-orcid":false,"given":"Martina","family":"Sanlorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-867X","authenticated-orcid":false,"given":"Vincenzo","family":"Panasiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-409X","authenticated-orcid":false,"given":"Alba","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-1035","authenticated-orcid":false,"given":"Silvia","family":"Alberti-Violetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-1949","authenticated-orcid":false,"given":"Mauro","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-0507","authenticated-orcid":false,"given":"Chiara","family":"Astrua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1706-656X","authenticated-orcid":false,"given":"Marco","family":"Rubatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-554X","authenticated-orcid":false,"given":"Luca","family":"Tonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-4910","authenticated-orcid":false,"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-7810","authenticated-orcid":false,"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-7694","authenticated-orcid":false,"given":"Simona","family":"Osella Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-6322","authenticated-orcid":false,"given":"Maria Teresa","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-4408","authenticated-orcid":false,"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.07.026_bib1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4161\/cbt.12.12.18144","article-title":"The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma","volume":"12","author":"Abraham","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jid.2020.07.026_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijd.IJD_73_17","article-title":"New targeted treatments for cutaneous T-cell lymphomas","volume":"62","author":"Bagot","year":"2017","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cyto.b.20395","article-title":"CD158k\/KIR3DL2 is a useful marker for identifying neoplastic T-cells in S\u00e9zary syndrome by flow cytometry","volume":"74","author":"Bahler","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jid.2020.07.026_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jid.2020.07.026_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/gcc.22679","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Bastidas Torres","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jid.2020.07.026_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2133.2001.04014.x","article-title":"The relevance of the CD4+ CD26- subset in the identification of circulating S\u00e9zary cells","volume":"144","author":"Bernengo","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jid.2020.07.026_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008397323199","article-title":"Prognostic factors in S\u00e9zary syndrome: a multivariate analysis of clinical, haematological and immunological features","volume":"9","author":"Bernengo","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ajcp\/106.6.739","article-title":"Immunophenotypic identification of Sezary cells in peripheral blood","volume":"106","author":"Bogen","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2020.07.026_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jid.2016.01.038","article-title":"Evaluation of immunophenotypic and molecular biomarkers for S\u00e9zary syndrome using standard operating procedures: a multicenter study of 59 patients","volume":"136","author":"Boonk","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2020.07.026_bib14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41419-018-1212-7","article-title":"Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in S\u00e9zary syndrome","volume":"9","author":"Caprini","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2020.07.026_bib16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in S\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"Cetin\u00f6zman","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","article-title":"New horizons in tumor microenvironment biology: challenges and opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jid.2020.07.026_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.14427","article-title":"Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides\/S\u00e9zary syndrome","volume":"175","author":"Child","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.07.026_bib20","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/jid.2009.290","article-title":"Regulation gone wrong: a subset of S\u00e9zary patients have malignant regulatory T cells","volume":"129","author":"Clark","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.07.026_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jid.2020.07.026_bib24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1468-3083.2010.03882.x","article-title":"Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langerin\u207a dendritic cells","volume":"25","author":"Der-Petrossian","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.07.026_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CCO.0000000000000161","article-title":"Recent advances in primary cutaneous T-cell lymphoma","volume":"27","author":"DeSimone","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/10428194.2017.1361022","article-title":"Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy","volume":"59","author":"Duvic","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2020.07.026_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib28","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/jdv.13597","article-title":"miR-155 expression in primary cutaneous T-cell lymphomas (CTCL)","volume":"31","author":"Fava","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.07.026_bib29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib30","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jid.2018.03.1526","article-title":"SATB1 in malignant T cells","volume":"138","author":"Fredholm","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2018.00198","article-title":"New therapies and immunological findings in cutaneous T-cell lymphoma","volume":"8","author":"Fujii","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2020.07.026_bib33","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41375-018-0066-4","article-title":"Novel phosphorylated TAK1 species with functional impact on NF-\u03baB and \u03b2-catenin signaling in human cutaneous T-cell lymphoma","volume":"32","author":"Gallardo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2020.07.026_bib34","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1038\/jid.2015.328","article-title":"Notch1 pathway activation results from the epigenetic abrogation of Notch-related microRNAs in mycosis fungoides","volume":"135","author":"Gallardo","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173171","article-title":"TP53 alterations in primary and secondary S\u00e9zary syndrome: a diagnostic tool for the assessment of malignancy in patients with erythroderma","volume":"12","author":"Gros","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2020.07.026_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0190-9622(96)90605-2","article-title":"Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses","volume":"35","author":"Harmon","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJM198105283042202","article-title":"Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells","volume":"304","author":"Haynes","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.026_bib38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1309\/AJCP09OTJOYAVZZK","article-title":"Simplified flow cytometric assessment in mycosis fungoides and S\u00e9zary syndrome","volume":"136","author":"Hristov","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2020.07.026_bib41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/bloodadvances.2018027482","article-title":"Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing","volume":"3","author":"Iyer","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jid.2020.07.026_bib42","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib43","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2020001441","article-title":"Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma","volume":"4","author":"Iyer","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jid.2020.07.026_bib44","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.21873\/anticanres.11006","article-title":"Expression of CD31 in mycosis fungoides","volume":"36","author":"Jankowska-Konsur","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jid.2020.07.026_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2020.07.026_bib46","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jid.2020.07.026_bib47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1309\/U1Y6-J4AG-5M4M-7AYV","article-title":"Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood","volume":"115","author":"Jones","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2020.07.026_bib48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jid.2020.07.026_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/10428194.2010.517877","article-title":"Evaluation of lymphangiogenic markers in S\u00e9zary syndrome","volume":"52","author":"Karpova","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2020.07.026_bib50","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib52","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S\u00e9zary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2020.07.026_bib53","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood-2010-09-305128","article-title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS\/RAF\/MEK signaling cascade","volume":"117","author":"Kiessling","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib54","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjd.13832","volume":"173","author":"Klemke","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib56","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jid.2020.07.026_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jid.2020.07.026_bib58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/leu.2011.237","article-title":"Regulatory T cells and immunodeficiency in mycosis fungoides and S\u00e9zary syndrome","volume":"26","author":"Krejsgaard","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2020.07.026_bib59","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","article-title":"Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma","volume":"20","author":"Krejsgaard","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2020.07.026_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1523-1747.2000.00818.x","article-title":"CD4\u00a0+ \/CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas","volume":"114","author":"Laetsch","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib61","article-title":"Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients","volume":"7","author":"Lefran\u00e7ois","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2020.07.026_bib62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/exd.13477","article-title":"Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome","volume":"27","author":"Lemchak","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib63","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jid.2020.07.026_bib65","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jid.2020.07.026_bib66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.1365-2133.2002.04994.x","article-title":"Dendritic cells and apoptosis in mycosis fungoides","volume":"147","author":"L\u00fcftl","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib67","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1158\/0008-5472.CAN-14-1456","article-title":"IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma","volume":"74","author":"Marie-Cardine","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2020.07.026_bib68","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1346-8138.12305","article-title":"Immunological milieu in mycosis fungoides and S\u00e9zary syndrome","volume":"41","author":"Miyagaki","year":"2014","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/bloodadvances.2018025114","article-title":"Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR","volume":"3","author":"Murray","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jid.2020.07.026_bib71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jaad.2011.06.014","article-title":"Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of S\u00e9zary syndrome","volume":"66","author":"Nagler","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib72","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of S\u00e9zary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib73","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jid.2020.07.026_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401415","article-title":"Inhibition of constitutively activated Stat3 correlates with altered Bcl-2\/Bax expression and induction of apoptosis in mycosis fungoides tumor cells","volume":"13","author":"Nielsen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2020.07.026_bib75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/0-306-47920-6_27","article-title":"CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients","volume":"524","author":"Novelli","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jid.2020.07.026_bib76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP1NA3YCHCDEIG","article-title":"Blood flow cytometry in S\u00e9zary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up","volume":"143","author":"Novelli","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2020.07.026_bib77","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0625.2012.01489.x","article-title":"CD158k\/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides","volume":"21","author":"Ortonne","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib79","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib80","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"P\u00e9rez","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib81","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00428-017-2107-1","article-title":"Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease","volume":"470","author":"Pileri","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jid.2020.07.026_bib82","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib83","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.0022-202X.2004.22326.x","article-title":"CD158k\/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome","volume":"122","author":"Poszepczynska-Guign\u00e9","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib84","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of gene mutations and fusion genes in patients with S\u00e9zary syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2020.07.026_bib86","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib87","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2020.07.026_bib88","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjd.17768","article-title":"The emerging role of microRNAs in the molecular diagnosis of mycosis fungoides","volume":"180","author":"Querfeld","year":"2019","journal-title":"Br J Dermatol"},{"issue":"Suppl.1","key":"10.1016\/j.jid.2020.07.026_bib89","first-page":"4076","volume":"130","author":"Querfeld","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib90","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1067\/mjd.2001.110900","article-title":"CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with S\u00e9zary syndrome","volume":"44","author":"Rappl","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib91","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jid.2020.07.026_bib130","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1139253","article-title":"Requirement of bic\/microRNA-155 for normal immune function","volume":"316","author":"Rodriguez","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jid.2020.07.026_bib92","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib93","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib94","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/jid.2014.487","article-title":"MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma","volume":"135","author":"Sandoval","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib95","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib96","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2009.06.082","article-title":"High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma","volume":"62","author":"Schlapbach","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib97","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2340\/00015555-1220","article-title":"Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome","volume":"92","author":"Schwingshackl","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2020.07.026_bib98","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2020.07.026_bib99","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jid.2018.03.1500","article-title":"MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma","volume":"138","author":"Shen","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib100","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.163.7.4073","article-title":"Depressed IL-12-mediated signal transduction in T cells from patients with S\u00e9zary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4","volume":"163","author":"Showe","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2020.07.026_bib101","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1203475419867610","article-title":"Immunotherapy for cutaneous T-cell lymphoma: current landscape and future developments","volume":"23","author":"Sivanand","year":"2019","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jid.2020.07.026_bib102","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2230.2005.01904.x","article-title":"Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with S\u00e9zary syndrome","volume":"30","author":"Sokolowska-Wojdylo","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib103","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0022-202X(89)90068-7","article-title":"CD4+ cutaneous T-cell lymphomas show the phenotype of helper\/inducer T cells (CD45RA-, CDw29+)","volume":"93","author":"Sterry","year":"1989","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib104","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1684\/ejd.2018.3444","article-title":"Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review","volume":"28","author":"Stewart","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.15785","article-title":"MicroRNA-155 potentiates tumour development in mycosis fungoides","volume":"177","author":"Tensen","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2020.07.026_bib108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.026_bib109","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.07.026_bib110","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/jid.2011.293","article-title":"Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in S\u00e9zary syndrome","volume":"132","author":"Van der Fits","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib111","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/jid.2012.203","article-title":"NOTCH1 signaling as a therapeutic target in S\u00e9zary syndrome","volume":"132","author":"Van der Fits","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib112","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archderm.1988.01670030039019","article-title":"Aberrant immunophenotypes in mycosis fungoides","volume":"124","author":"Van der Putte","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib113","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaqu\u00e9","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib114","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","article-title":"CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior","volume":"19","author":"Vermeer","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10428194.2017.1334123","article-title":"CD4+CD26- lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma","volume":"59","author":"Vonderheid","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2020.07.026_bib116","series-title":"Basic Mechanisms of Physiologic and aberrant lymphoproliferation in the skin","first-page":"275","article-title":"Analysis of clinical, histopathologic and immunopathologic parameters in erythrodermic variants of cutaneous T-cell lymphoma with implications for staging","author":"Vonderheid","year":"1994"},{"key":"10.1016\/j.jid.2020.07.026_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/10428194.2013.790541","article-title":"Prognostic factors and risk stratification in early mycosis fungoides","volume":"55","author":"Vonderheid","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2020.07.026_bib118","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.07.026_bib119","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib120","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood 2019;134:1112]","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib121","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/intimm\/dxm091","article-title":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs","volume":"19","author":"Wong","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.jid.2020.07.026_bib122","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0190-9622(90)70080-2","article-title":"Leu-8\/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides\/S\u00e9zary syndrome relative to normal blood values","volume":"22","author":"Wood","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib123","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in S\u00e9zary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.07.026_bib124","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.1990.tb06332.x","article-title":"The distribution of CD45R, CD29 and CD45RO (UCHL1) antigens in mature CD4 positive T-cell leukaemias","volume":"74","author":"Worner","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2020.07.026_bib125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0190-9622(07)80011-9","article-title":"CD7-positive S\u00e9zary syndrome with a Th1 cytokine profile","volume":"34","author":"Yagi","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.07.026_bib126","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jdermsci.2017.07.013","article-title":"Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides","volume":"88","author":"Yanagi","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2020.07.026_bib127","first-page":"553","article-title":"The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage","volume":"18","author":"Zhang","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jid.2020.07.026_bib128","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.026_bib129","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20319849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20319849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:19:52Z","timestamp":1758302392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20319849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0022202X20319849"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.07.026","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and\/or S\u00e9zary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}